Skip to content
Screener

OptimizeRx OPRX Q1 2026 earnings

Reported May 12, 2026 · After market close

Revenue$19.8MBeat by $1.1M
EPS$0.14Beat by $0.13
Revenue estimate$18.7M
EPS estimate$0.01

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$21.6M
EPS estimate$0.19

Financials

Q1 2026

Income statement

See full
Revenue$19.8M-9.5%
Gross profit$14.9M+11.9%
Operating income$396.0K+119%
Net income-$495.0K+77.5%
EPS (diluted)-$0.03+75.0%

Balance sheet

See full
Cash & equivalents$20.2M+21.7%
Total debt$23.7M-27.7%
Total equity$129.6M+11.5%
Total assets$167.3M-0.3%

Cash flow

See full
Operating cash flow-$467.0K-112%
CapEx$21.0K-22.2%
Free cash flow-$488.0K-113%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$117.83M-26.4%
Enterprise value$121.37M-31.2%
P/E17.2×—
P/S1.1×-1.0×

Profitability

See full
Gross margin70%+14.1pp
Operating margin13.2%—
Net margin6.4%+3.6pp
FCF margin13.4%+4.8pp

Returns & leverage

See full
Return on equity5.6%+3.3pp
Debt / equity0.2×-0.1×
Current ratio5.4×+2.6×

FAQ

When did OptimizeRx report Q1 2026 earnings?
OptimizeRx (OPRX) reported Q1 2026 earnings on May 12, 2026 after market close.
What were OptimizeRx's Q1 2026 revenue and EPS?
OptimizeRx reported revenue of $19.8M and eps of $0.14 for Q1 2026.
Did OptimizeRx beat estimates in Q1 2026?
Revenue beat the consensus estimate of $18.7M by $1.1M. EPS beat the consensus estimate of $0.01 by $0.13.
How did OptimizeRx's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 9.5% from $21.9M a year earlier and eps grew 75.0% from $0.08.
Where can I find OptimizeRx's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001448431-26-000009) and the 10-Q periodic report (0001448431-26-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.